The new guidelines indicate that blood-based ctDNA testing is preferred due to greater sensitivity. Guardant360® CDx test is the only FDA-approved CDx to identify patients with ESR1 mutations who may benefit from treatment with ORSERDU™ (elacestrant). bit.ly/3Jm8r5l